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Desmoid-type fibromatosis (DTF) is a rare, soft tissue tumor of mesenchymal origin which
is characterized by local infiltrative growth behavior. Besides “wait and see,” surgery
and radiotherapy, several systemic treatments are available for symptomatic patients.
Recently, targeted therapies are being explored in DTF. Unfortunately, effective treatment
is still hampered by the limited knowledge of the molecular mechanisms that prompt DTF
tumorigenesis. Many studies focus on Wnt/β-catenin signaling, since the vast majority of
DTF tumors harbor a mutation in the CTNNB1 gene or the APC gene. The established
role of the Wnt/β-catenin pathway in DTF forms an attractive therapeutic target, however,
drugs targeting this pathway are still in an experimental stage and not yet available in the
clinic. Only few studies address other signaling pathways which can drive uncontrolled
growth in DTF such as: JAK/STAT, Notch, PI3 kinase/AKT, mTOR, Hedgehog, and the
estrogen growth regulatory pathways. Evidence for involvement of these pathways in
DTF tumorigenesis is limited and predominantly based on the expression levels of key
pathway genes, or on observed clinical responses after targeted treatment. No clear
driver role for these pathways in DTF has been identified, and a rationale for clinical
studies is often lacking. In this review, we highlight common signaling pathways active in
DTF and provide an up-to-date overview of their therapeutic potential.
Keywords: desmoid-type fibromatosis, signaling pathways, desmoid tumor, CTNNB1mutation, review, ß-catenin,
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INTRODUCTION
Desmoid-type fibromatosis (DTF) is a clonal fibroblastic proliferation of the soft tissues that
arises in musculoaponeurotic structures (1). It has a mesenchymal origin since DTF tumors
express cell surface markers and genes that are characteristic of mesenchymal stem cells (2). The
incidence in the Dutch population is 5 patients per million people per year (3). Unfortunately
worldwide epidemiological data is lacking. The abdominal wall and the trunk are themost common
localizations and symptoms can vary, depending on tumor location and size (4, 5). Roughly
two types can be distinguished; sporadic and hereditary DTF. The first type is considered to be
a monoclonal disorder, since it derives from a single progenitor cell (6). This “sporadic” type
is commonly localized extra-abdominally or in the abdominal wall (5). The precise etiology of
sporadic DTF remains tenuous. Several studies report correlations with (spontaneous or iatrogenic)
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trauma and hormonal status (7–10). The hereditary type occurs
more frequent in patients with familial adenomatous polyposis
(FAP), and causes intra-abdominal DTF tumors. This DTF type
is an autosomal dominant disorder caused by germline mutation
of the adenomatous polyposis coli (APC) gene, and is associated
with the formation of hundreds of colon polyps which can
transform into malignant colorectal tumors in time [reviewed by
DeMarchis et al. (11) and Lips et al. (12)]. The cumulative rate of
DTF in FAP patients is 20.6% at 60 years of age (13).
Desmoid-type fibromatosis is considered to be a borderline
tumor because of its incapability to metastasize (1). Themortality
of this disease is low and seldom described in literature. However,
local aggressive growth can cause significant morbidity by
infiltrating surrounding structures, causing pain or functional
loss. Currently, “wait and see” is the first line therapy in case
of asymptomatic DTF. Several retrospective studies report that
a minority of patients on a “wait and see” protocol experience
progression and that progression usually occurs within 2 years
after tumor development (14). Additionally, up to one third
of patients experience disease regression without any form of
treatment (15–17). Three prospective studies investigating a
“wait and see” approach (NCT02547831, Italy; NTR 4714, the
Netherlands; NCT01801176, France) examine the natural growth
behavior of DTF and their relationship with CTNNB1mutations
(18–20). Surgery is the treatment of choice in case of failure of
the “wait and see” management (21). Radiotherapy is mainly
used as an adjuvant treatment in case of incomplete surgical
resection. Radiotherapy, as a single treatment modality, may be
considered for patients in whom local control is the primary
treatment goal (21). When both surgery and radiotherapy
are not an option due to tumor localization (e.g., near vital
structures), or because of comorbidities, several other treatment
options are available like local cryoablation and partial systemic
chemotherapy via isolated limb perfusion (21). Although not
widely used, as the evidence for their effect in DTF is only
based on small patient series, some patients benefit from
these local therapies for example when limb salvage is the
treatment goal (22–25). Besides targeted drugs, other systemic
options include more classic chemotherapeutic compounds like
vinblastine, vinorelbine, methotrexate, doxorubicin, dacarbazine,
either as a single agent or as combination therapy (21). Although
most studies describe small retrospective case series and include
patients who received other treatments prior to their cytotoxic
treatment, multiple studies indicate a potential effect of these
drug regimens (26–29).
The aggressive growth behavior, in combination with the high
recurrence rate, creates the need for effective drugs targeting the
molecular mechanisms that drive tumorigenesis (30, 31). This is
especially true for large, symptomatic tumors which cannot be
treated surgically or with radiotherapy. As stated above, several
systemic options are available with variable efficacy in different
patients, but no consensus about the nature and the sequence
of systemic treatments has been established (21). As of yet, the
exact working mechanisms of these systemic agents in DTF
remain unclear.
A better understanding of the molecular mechanisms
that prompt tumorigenesis and influence DTF progression
will contribute to the development and implementation of
new targeted therapies. This review comprehensively screened
the available literature regarding active cell signaling and
biochemical pathways and reviews pathway-specific targeted
drugs investigated in DTF. Additionally, the challenges of DTF
research, as well as the future perspectives, are discussed. The
abbreviations used in the text, tables and figures are explained
in Appendix 1.
THE WNT/β-CATENIN SIGNALING
PATHWAY IN DESMOID-TYPE
FIBROMATOSIS
The Wnt/β-Catenin Signaling Pathway
The canonical Wnt/β-catenin pathway coordinates cell fate
decisions during the developmental process and in adult
homeostasis. Target genes of this signaling pathway are involved
in regulating the balance between self-renewal, differentiation,
apoptosis, and in stem cell maintenance [reviewed by Nusse and
Clevers (32) and Steinhart and Angers (33)]. Activation of the
Wnt/β-catenin pathway involves a Wnt ligand binding to the
transmembrane receptor Frizzled, forming a complex with a co-
receptor that is the LDL receptor-related protein 5 or 6 (LRP5
and LRP6). The β-catenin protein is a keymediator in theWnt/β-
catenin signaling pathway, and its stability is normally regulated
by a degradation complex consisting of the tumor suppressor
APC, a scaffolding protein axin, and two constitutively active
serine-threonine kinases i.e., casein kinase 1α (CK1α/δ), and
glycogen synthase kinase 3 (GSK3). Within this complex, β-
catenin is sequentially phosphorylated by CK1 and GSK3 on
serine/threonine residues (Ser45, Thr41, Ser37, Ser33), thus
forming a docking site for the E3 ubiquitin ligase; β-TrCP. This
ubiquitinylates β-catenin which is subsequently degraded by the
proteasome. Activation of theWnt/β-catenin pathway by binding
of the Wnt ligand to the frizzled/LRP heterodimer recruits the
degradation complex to the membrane via the disheveled protein
(DVL) disrupting the degradation complex and consequently
the phosphorylation of β-catenin, leading to its stabilization
and translocation into the nucleus. In the nucleus it operates
as a transcriptional activator, bound to members of the T-cell
factor/lymphoid enhancer factor (TCF/LEF) transcription factor
family, and possibly to other co-activators of Wnt target genes
[reviewed by Nusse and Clevers (32)].
The Wnt/β-Catenin Signaling Pathway in
Cancer
The Wnt/β-catenin signaling pathway contributes to cancer
by promoting progression of cells through the cell cycle, by
inhibiting of apoptosis via the expression of anti-apoptotic genes,
by affecting cell proliferation via the expression of growth factors
and their corresponding receptors, by influencing cell motility
through the expression of cell adhesion and extracellular matrix
proteins and via stem cell maintenance [reviewed by Nusse
and Clevers (32)]. Aberrant signaling of the Wnt/β-catenin
pathway has been implicated in several epithelial tumors [e.g.,
colorectal carcinoma (34) and endometrial carcinoma (35)] and
in mesenchymal tumors [e.g., osteosarcomas (36, 37), malignant
fibrous histiocytomas and liposarcomas (38)].
Frontiers in Oncology | www.frontiersin.org 2 May 2019 | Volume 9 | Article 397
Timbergen et al. Signaling Pathways in Desmoid-Type Fibromatosis
The Wnt/β-Catenin Signaling Pathway in
Desmoid-Type Fibromatosis
The relationship between the Wnt/β-catenin signaling pathway
and DTF has been extensively studied. It is believed that this
pathway is crucial to DTF pathogenesis because of the fact
that the vast majority (about 85%) of DTF tumors harbor a
mutation in exon 3 of the CTNNB1 (β-catenin) gene, making
the protein more resistant to proteolytic degradation (39–41).
Less frequently, loss-of-function mutations in the APC tumor
suppressor gene are observed, most commonly in the context of
FAP (12). In both cases, β-catenin translocates into the nucleus
aberrantly activating target genes. This nuclear accumulation
can be determined by immunohistochemistry (IHC), and serves
as a diagnostic tool differentiating DTF from other bone-, soft
tissue and fibrous tumors (42). The group of wild-type (WT)
ß-catenin DTF, comprises about 15% of all DTF tumors, and
is defined as “having no CTNNB1 mutations in exon 3.” The
number of DTF patients assigned to this group decreases over
time since next generation sequencing is able to detect β-catenin
mutations located on exon 3, in tumors where the traditional
Sanger sequencing method is not sensitive enough (43, 44).
Interestingly, the β-catenin mutations observed in DTF are
almost exclusively confined to residues T41 and S45, while
alterations at other N-terminal phosphorylation residues, that is
D32-S37, are rarely observed. Recently, Rebouissou et al. showed
in liver cancers that the T41 and S45mutants activate the pathway
only weakly compared to others (45). Apparently, this weak
activation is ideal for DTF outgrowth in line with the “just-
right” signaling hypothesis that postulates that each tumor type
selects for an optimal level of β-catenin signaling that is ideal
for tumor initiation and progression (46). In accordance, the
APC mutant proteins observed in DTF retain some functionality
in regulating β-catenin levels. The specific β-catenin mutation
may be of clinical relevance since several groups reported a
higher recurrence rate in CTNNB1 S45F mutated DTF tumors
compared to other CTNNB1 (T41A) mutated tumors and WT
DTF (30, 47–49). This issue is however still under debate as others
have reported contradictory results (41, 50).
Using a β-catenin reporter assay in primary DTF cultures,
Tejpar et al. validated the enhanced β-catenin signaling present
in DTF. They also showed that in the nucleus, β-catenin
is mainly associated with TCF7L1 (also known as TCF3) to
regulate target genes. Expression of TCF7 (TCF1) and LEF1
could not be identified, while solely a minority of DTF samples
expressed TCF7L2 (TCF4) (51). Others found that several matrix
metalloproteinases (MMP-3, MMP-7, andMMP-9) are expressed
in DTF implying a role for MMP’s in DTF invasiveness (52,
53). In fact Kong et al. showed that MMP inhibition decreases
tumor invasion and motility (52). Matono et al. showed that
MMP7 is more abundantly expressed in CTNNB1 mutated DTF
compared to CTNNB1 WT, and hypothesized a correlation
between MMP7 and prognosis, as previously was demonstrated
in pancreatic cancer (54, 55). The MMP-inhibitor ilomastat
(galardin/GM6001) was investigated in two studies, showing
a decrease in DTF-cell (human and murine) migration and
invasion capability (52, 53). In Apc+/Apc1638N mutant mice, DTF
tumor volume was decreased (Table 1) (52).
Pharmacological Options Targeting the
Wnt/β-Catenin Signaling Pathway
Although many studies implicated aberrant Wnt/β-catenin
signaling in DTF tumorigenesis, therapeutic targeting of this
pathway remains challenging. Wnt/β-catenin target-genes that
do form attractive therapeutic targets in DTF are cyclooxygenase
(COX), a member of the COX enzyme family (COX1 and
COX2) and the vascular endothelial growth factor (VEGF), a
protein that regulates angiogenesis. A role of COX in DTF
has been indicated by the expression of COX2 and by the
expression of phosphorylated, and thus activated, associated
growth factors receptors, such as the platelet derived growth
factor receptor α and ß (PDGF-α and PDGF-ß) (56, 73).
Activation of their receptors (PDGFR-α/PDGFR-ß) takes place
by an autocrine/paracrine loop and is initiated by COX2
overexpression due to Wnt/β-catenin deregulation (56, 73).
Inhibition of COX with sulindac decreased cell proliferation in
DTF cell culture and therefore forms an attractive therapeutic
target in DTF, especially because COX inhibitors are already
widely used in the clinic (56, 57). Halberg et al. reported
decreased DTF tumor numbers in ApcMin/+p53−/− mice
treated with piroxicam, a drug which is a non-steroidal anti-
inflammatory drug (NSAID) which works by inhibiting both
prostaglandins and the COX enzyme (Table 1) (58).
A preclinical study by Poon et al. used the non-opioid
analgesic drug nefopam (benzoxazocine class), and reported a
decrease in ß-catenin levels and cellular proliferation rate, as well
as a reduction in tumor number and volume in Apc+/Apc1638N
mice (Table 1) (60). The working mechanism of this drug in
DTF has not been entirely clarified yet, but is presumably
due to an inhibition of serine-9-phosphorylation of GSK3-β
(Figure 1) (60).
Overexpression of VEGF has been correlated with ß-catenin
nuclear staining in DTF (74). Additionally, microvessel density, a
phenomenon correlated to angiogenesis, was shown to be higher
in samples with VEGF overexpression. This high vascularity
potentially increases the growth potential of DTF tumors (74).
These findings reveal a possible new treatment strategy for DTF
by interfering with angiogenesis. Endostatin, an anti-angiogenic
protein with the ability to inhibit the Wnt/β-catenin signaling
pathway in colorectal cancer cells, directed the induction of
cell death in primary FAP-associated DTF-cells in culture (59).
Endostatin has been proven to be well-tolerated in a Phase 1
study, with minimal toxicities in patients with solid tumors other
than DTF; however no studies report the use of endostatin for
DTF in the clinic (75).
The blockage of Wnt/β-catenin signaling with the truncated
Frizzled 9 receptor fused to the IgG1 Fc region (ipafricept, OMP-
54F28), was recently tested in a Phase 1 study for solid tumors
(Table 2). In this study, two patients with DTF were included that
both exhibited stable disease, although it is unclear if this can be
directly attributed to the treatment (76).
While the above-mentioned treatments, targeting Wnt/β-
catenin targets constitute attractive therapeutic possibilities, no
prospective clinical trials using these treatment strategies in
sporadic DTF have been designed. Experimental inhibitors of
Wnt/β-catenin signaling have been developed, however, systemic
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TABLE 1 | Overview of drugs used in in vitro/vivo studies targeting a signaling pathway in DTF.
Drug References Setting Effect
WNT/ß-CATENIN SIGNALING PATHWAY
MMP inhibitor
Ilomastat/Galardin (GM6001)
(52) Apc+/Apc1638N mice
Murine PCC from DTF and NF
↓ DTF cell invasion and motility
↓ Tumor volume in mice
(53) Human PCC from DTF and
normal fascia
↔Cell growth
↓ DTF cell invasion
NSAID
Sulindac/Indomethacin/DFU
(56) Human PCC from DTF and
normal marginal tissues
Apc+/Apc1638N-Cox2−/− and
Apc+/Apc1638N
-Cox2+/+ mice
↓ DTF cell and NF proliferation
↔ Apoptosis in DTF cells and NF
↔ Tumor number in mice (sulindac)
↓ Tumor volume in mice (sulindac)
NSAID
Sulindac
(57) Human PCC from DTF, CRC ↓ DTF cell growth
↔ Cell morphology
NSAID
Piroxicam (+DFMO)
(58) Apc−/+p53+/−,
Apc+/+p53+/−,
Apc−/+p53+/+ mice
↓ DTF tumor number
Angiostatic factor
Endostatin
(59) Human PCC from FAP-related
DTF and CRC
↑ Apoptosis (CRC cultures)
↑ Cell death (DTF cultures)
Benzoxazocine
Nefopam
(60) Human PCC from DTF and NF
Apc1638N mice
↓ Cell proliferation, modest change in apoptosis
↓ ß-catenin protein level
↓ tumor number and volume (mice)
HEDGEHOG SIGNALING PATHWAY
Hedgehog
inhibitor
Triparanol
(61) Human PCC from DTF
Apc+/1638N; Gli2+/− and
Apc+/1638N; Gli2+/+ mice
↓ Tumor volume (Apc+/1638N mice)
↓ Number of tumors (Apc+/1638N; Gli2+/−)
↓ Number of tumor cells, viability, proliferation rate (DTF
cells)
↔ Apoptosis (DTF cells)
NOTCH SIGNALING PATHWAY
γ-secretase
inhibitor
PF-03084014
(62) Human PCC from DTF ↓ Notch signaling (↓ NICD and Hes1 expression)
↑ Cell cycle arrest
↓ Cell growth, migration and invasion
JAK/STAT SIGNALING PATHWAY
Cytokines
Interferon-ß
(63) Human PCC from DTF and NF
Apc/Apc1638N, Apc1638N;
Ifnar1−/− and
Apc/Apc1638N; Ifnar1+/+
↔ Apoptosis (human vs. murine DTF and NF)
↓ Cell proliferation (human/murine DTF and NF)
PI3K/AKT/mTOR SIGNALING PATHWAYS
Tyrosine kinase
inhibitor
Sorafenib (±Everolimus)
(64) Human PCC from DTF ↓ DTF cell proliferation and invasion (sorafenib)
↓ mTOR signaling [↓ phospho-S6K levels (everolimus)]
GROWTH REGULATORY SIGNALING PATHWAYS
Cytokines
TGF-ß1
(65) Human PCC from DTF, fibroma,
NF
↔ Cell proliferation in DTF, fibroma and NF cell culture
↑ GAG accumulation in extra-cellular matrix
↑ Collagen synthesis
(66) Human PCC from DTF and NF ↑ Active unphosphorylated fraction of ß-catenin
Cytokines
rhEGF/rhTGF-α
(67) Human PCC from DTF Up- and down regulation of genes in response to
stimulation with rhEGF/rhTGF-α
Cytokines
rhEGF/AG1478/SB431542
(68) Human PCC from DTF ↑ DTF cell motility (rhEGF)
ESTROGEN DRIVEN PATHWAY
Anti-estrogen
Tamoxifen/Toremifene
(69) Human PCC from DTF ↓ Cell growth (tamoxifen ± estrogen)
↔ Cell growth (toremifene ± estrogen)
Anti-estrogen
Toremifene
(70) Human PCC from DTF, fibroma
and NF
↔ Cell proliferation (3H-tymidine incorporation)
↓ GAG (DTF, fibroma and NF cultures)
↓ Collagen production (3H-proline incorporation)
↓ TGF-ß1 levels in culture medium
↓ TGF-ß1 mRNA expression levels
↓ TGF-ß1 receptor affinity
(Continued)
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TABLE 1 | Continued
Drug References Setting Effect
(71) Human PCC from DTF and NF ↑Cell death (DTF and NF culture)
↓ Collagen production (3H-proline incorporation)
↓ Procollagen α1 mRNA expression (DTF culture)
↓ Type I and III collagen
↑ Collagenase activity
↔ MMP-1, ↑ MMP-2, ↓ TIMP-1
(72) Human PCC from DTF,
Gardner-syndrome related
fibroblast and NF
↓ GAG synthesis and secretion
↓ Active TGF-ß1,↔ total (active + latent) TGF-ß1
↓ Number TGF-ß1 receptors (DTF cells)
↓ TNF-α production
↓, decrease; ↑, increase; ↔, no effect; CRC, colorectal cancer; DFMO, Difluoromethylornithine; DFU, selective COX-2 blocker (5,5-dimethyl-3-(3-uorophenyl)4-(4-
methylsulphonyl)phenyl-2(5H)-furon one); DTF, desmoid-type fibromatosis; FAP, familial adenomatous polyposis;, GAG, glycosaminoglycan; PCC, primary cell culture; NF, normal
fibroblast; NSAID, non-steroidal anti-inflammatory drug.
Target genes e.g.:
COX
WISP1
ADAM12
VEGF
TCF-3
MMP
SOX-11
Wnt
Wnt
Wnt
Wnt
Wnt
Ipafricept, OMP-54F28
6/
5
P
R
L
DVL
GSK3ß 
APCAxin
CK1
ß-catenin
TCF3
CBP
nucleus
cytoplasm
cell membrane
Angiostatic factor:
Endostatin
ß-catenin
ß-catenin
ß-catenin
ß-catenin
ß-catenin
MMP inhibitor:
Ilomastat /Galardin
Frizzled
ß-catenin
ß-TrCP
NSAIDs:
Meloxicam
Piroxicam
Sulindac
Benzoxazocine:
Nefopam
FIGURE 1 | A schematic presentation of the Wnt/β-catenin signaling pathway and the drugs that target this pathway in DTF. The graph shows that ipafricept
(OMP-54F28), inhibits Wnt signaling by acting as a decoy receptor inhibiting Wnt signaling through the Frizzled 9 receptor. NSAIDs, like meloxicam, the angiogenesis
inhibitor endostatin and MMP inhibitors act on target genes of the Wnt signaling pathway. The drug Nefopam, a non-opioid analgesic drug of the benzoxazocine class
suppresses the effect of high levels of β-catenin.
abolition of Wnt secretion is not preferable since this will result
in defects in gut homeostasis, affects the immune system and
affects both ß-catenin-dependent and independentWnt signaling
[reviewed by Zimmerli et al. (90) and Enzo et al. (91)]. Figure 1
displays the Wnt/β-catenin signaling pathway and putative drug
targets in the context of DTF.
THE HEDGEHOG SIGNALING PATHWAY IN
DESMOID-TYPE FIBROMATOSIS
The Hedgehog Signaling Pathway
The Hedgehog (Hh) signaling pathway plays an essential role
in embryonic development, in adult tissue homeostasis, tissue
renewal and tissue regeneration. Precursor proteins of Hh
ligands, including Sonic (Shh), Indian (Ihh), and Desert (Dhh),
undergo autocatalytic cleavage and cholesterol alterations at
the carboxy terminal end, and palmitoylation at their amino
terminal end. This process results in a dually-lipidated protein,
which is released from the secreting cell surface. Subsequently,
the Hh ligands interact with cell surface proteins like Glypican
and the proteins of the heparin sulfate proteoglycan family
enhancing their stability and promoting internalization when
bound to Patched (PTCH1). Binding of Hh proteins to the
canonical receptor PTCH1 and to co-receptors GAS1, BOC,
and CDON initiates Hh signaling. This results in the release
of PTCH1 mediated repression of the transmembrane protein
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TABLE 2 | Overview of drugs used in clinical trials targeting signaling pathways in DTF.
Drug References Setting Tumor type N of DTF
patients
Efficacy in DTF
WNT/ß-CATENIN SIGNALING PATHWAY
Frizzled 9 receptor blocker
Ipafricept (OMP-54F28)
(76) Phase 1 Advanced solid tumors
(n = 26)
2 N = 2 SD (>6 months)
NOTCH SIGNALING PATHWAY
PF-03084014 (77) Phase 1 DTF 7 ORR 71.4% (95%CI 29–96.3%)
N = 5 PR, median TTR 9.9 months
N = 1 PD
(78) Phase 2 DTF 17 n = 5 PR (after a median of 32 cycles, 95
weeks), n = 11 SD
PI3K/AKT/mTOR SIGNALING PATHWAYS
Receptor Tyrosine Kinase
inhibitor
Imatinib
(79) Phase 2 DTF 40 n = 2 TS (<1 year)
At 3 months: n = 1 CR, n = 3 PR, n = 28 SD,
n = 5 PD
3-months NPRR 91% (95% CI 77–96),
6-months NPRR 80%, 12-months NPRR 67%
(80) Phase 2 DTF 51 At 2-months: n = 48 SD
2-months PFS 94%, 4-months PFS 88%, 1
year PFS 66%
(81) Phase 2 DTF 19 n = 3 PR, n = 4 SD (>1 year), 1-year disease
control rate 36.8%, TTF 325 days
(82) Phase 2 Imatinib-sensitive
tumors (n = 186)
20 DTF patients: n = 2 PR, n = 8 SD, n = 7 PD,
n = 3 unknown.
Median TTP 9.1 months (95% CI
2.9–17.0 months).
Imatinib (+nilotinib) (83) Phase 2 DTF 39 OS 100%, PAR at 6 months: 65%
At 21 months: n = 7 PR, ORS 19%
n = 8 imatinib + nilotinib due to PD under
imatinib 3-months PAR 88%
Imatinib + gemcitabine (I +
G) or Imatinib+ doxorubicin
(I + D)
(84) Phase 1 solid tumors (n = 16) 1 (I + G) DTF patients: ceased treatment due to
dose-limiting toxicity (grade 2 neutropenia)
Sunitinib (85) Phase 2 Non-GIST sarcomas (n
= 53)
1 DTF patients: n = 1 NR
(86) Phase 2 advanced DTF 19 Median FU 20.3 months (1.8–50.7 months),
2-year PFS 74.7%, OS 94.4%. n = 5 PR,
n = 8 SD, n = 3 PD, n = 3 not evaluable.
Median duration of the response 8.2 months
(range 2.0–17.3 months)
Sorafenib (+topotecan) (87) Phase 1 Pediatric solid
malignancies (n = 13)
2 DTF patients: n = 1 PR
(88) Phase 3 Advanced and
refractory DTF
87 2-year PFS of sorafenib 81% (95%CI 69–96%)
vs. placebo 36% (95%CI 22–57%)
ORR of sorafenib 33% (95% CI 20–48%) vs.
placebo 20% (95% CI 8–38%)
ESTROGEN DRIVEN PATHWAY
Anti-estrogen + NSAID
Tamoxifen + Sulindac
(89) Phase 2 Pediatric DTF 59 N = 4 PR, n = 1 CR
2-year PFS 36%, OS 96%
CI, confidence interval; CR, complete response; DTF, desmoid-type fibromatosis; GIST, gastro-intestinal stromal tumor; N, number of patients; NPRR, non-progressive response rate;
NR, no response; ORR, objective response rate; ORS, overall response rate, OS, overall survival; PAR, progression arrest rate; PD, progressive disease; PFS, progression free survival;
PR, partial response; SD, stable disease; TS, treatment stop; TTF, time to treatment failure; TTP, Time to progression; TTR, time to recurrence.
Smoothened (SMO), a G-protein coupled receptor (GPCR)-
like protein, which consequently leads to an accumulation
of SMO in the cilia and phosphorylation of its cytoplasmic
tail. Smoothened, regulates the downstream signal transduction
which dissociates glioma associated oncogene (GLI) proteins,
from kinesin-family protein, KIF7 and SUFU. GLI proteins serve
as bifunctional transcription factors, capable of activating and
repressing transcription, and form a key intracellular component
of the Hh pathway [reviewed by Wu et al. (92) and Briscoe and
Thérond (93)].
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The Hedgehog Signaling Pathway in
Cancer
Aberrant Hh signaling in cancer is attributed to an increased
endogenous Hh ligand expression, or to activating mutations
of Hh pathway components [reviewed by Wu et al. (92)].
Aberrant uncontrolled activation of Hh has been described
in numerous tumor types including; rhabdomyosarcoma
(94), colorectal cancer (95), basal cell carcinoma (96), and
medulloblastoma (97).
The Hedgehog Signaling Pathway and Its
Role and Therapeutic Potential in
Desmoid-Type Fibromatosis
As the Hh pathway has the ability to maintain mesenchymal
progenitor cells in a less differentiated state with greater
proliferative capacity, it is possible that it influences proliferation
of DTF cells in a similar manner because of the mesenchymal
origin of these cells (61). Ghanbari et al. showed that Hh signaling
is active in DTF by identifying a significant upregulation of
Hh target genes GLI1, PTCH1, and Hedgehog interacting protein
(HHIP) in human DTF samples compared to adjacent normal
tissues. Additionally it was demonstrated that expression of Gli1,
Gli2, and Ptch1 in mouse (Apc+/1638N) tumors was upregulated
compared to normal tissue. In vivo, pharmacological inhibition
of Hh with triparanol, which works by interference with the
post-translational modification of Hh signaling molecules and
with the sterol-sensing domain of the receptor PTCH1, led
to a reduction in tumor volume in Apc+/1638N mice. Genetic
approaches to reduce Hh signaling in DTF, using Apc+/1638N;
Gli2+/− mouse models, gave rise to the development of fewer
and smaller tumors (Table 1) (61, 98). Currently, inhibition of the
Hh signaling pathway acts via the pharmacological inhibition of
SMO, however no clinical trials studying Hh inhibitors in DTF
have been carried out. Figure 2 displays the Hh pathway and
proposed working mechanism of target drugs in DTF.
THE NOTCH SIGNALING PATHWAY IN
DESMOID-TYPE FIBROMATOSIS
The Notch Signaling Pathway
Notch signaling is essential for regulating cell-fate during tissue
development and for managing cell proliferation, differentiation
and survival, neurogenesis and homeostasis in adult tissues
[reviewed by Artavanis-Tsakonas et al. (99)]. There are four
mammalian transmembrane Notch receptors (Notch receptor
family type 1–4; NOTCH 1–4). Each receptor is a Ca2+-
stabilized heterodimer containing three domains: an extracellular
(NECD), a transmembrane (NTMD) and an intracellular
domain (NICD) [reviewed by Takebe et al. (100)]. These
receptors can interact with ligands; members of the Delta-like
(DLL1, DLL3, and DLL4), and the Jagged (JAG1 and JAG2)
families. In case of ligand binding, the receptor undergoes two
processing steps. The first cleavage is mediated by a member
of the disintegrin and metalloproteinase family (ADAM10 or
ADAM17) and releases the NECD which remains bound to
its ligand and is internalized by endocytosis in the cell that
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FIGURE 2 | A schematic presentation of the Hedgehog signaling pathway and
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sends the signal. Subsequently in the receiving cell, a presenilin-
dependent γ-secretase complex, removes the NICD from the
NTMD. This NICD is translocated into the nucleus where
it interacts with the CSL (CBF1/Suppressor of hairless/Lag-1)
repressor complex; converting it into an activation complex
that interacts with a co-activator protein mastermind-like 1
(MAML1). These interactions results in the transcriptional
activation of several Notch target genes, such as MYC,
p21, HRT, Notch receptors, Notch ligands, cyclin D1, and
HES-family members [reviewed by Takebe et al. (100) and
Ranganathan et al. (101)].
The Notch Signaling Pathway in Cancer
Deregulation of the Notch signaling pathway is described in
hematologic malignancies, notably T-cell acute lymphoblastic
leukemia which harbors an activating mutation in NOTCH1
that result in a constitutive Notch signaling pathway activity
(102). Although activating mutations in members of the Notch
family are uncommon in solid tumors, Notch signaling may
play a role in tumorigenesis [reviewed by Egloff and Grandis
(103)]. For example, NOTCH3 transcript and protein levels are
upregulated in a subset of colorectal cancers promoting tumor
growth (104).
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The Notch Signaling Pathway and Its Role
and Therapeutic Potential in Desmoid-Type
Fibromatosis
Inhibition of Notch signaling forms an appealing therapeutic
approach. Small molecular inhibitors, including γ-secretase
inhibitors (GSI), siRNAs, and monoclonal antibodies against
Notch receptors and ligands have been developed [reviewed by
Yuan et al. (105)]. Particularly GSI’s are of interest as these drugs
inhibit the final Notch processing step by which NICD is released
to act in the nucleus, consequently blocking Notch signaling. A
number of GSI’s (e.g., MK-0752 and RO4929097) have already
been studied in solid cancers other than DTF in early phase
clinical trials (106, 107).
Few studies investigated the role of the Notch signaling
in DTF, however, DTF tumors have been shown to express
NOTCH1 and its downstream target HES1 (108). Preliminary
evidence, from a phase 1 clinical trial indicated a partial response
in five out of seven DTF patients to the oral GSI PF-03084014
(Table 2) (109). This prompted an in vitro study performed by
Shang et al. which demonstrated a significant higher expression
of nuclear HES1 in DTF tissues compared to scar tissue by
IHC and reported expression of NOTCH1, JAGGED1, and HES1
in DTF cells by Western Blot analysis. Additionally, it was
demonstrated that PF-03084014, decreased NICD and HES1
expression in a dose dependent manner in DTF cells, and that
Notch signaling inhibition contributed to impaired DTF cell
proliferation by inducing a cell cycle G1 arrest and decreasing
migration and invasion (Table 1) (62). Two other clinical trials
(a phase 1 trial with seven DTF patients and phase II trial with
17 DTF patients) showed promising results with a significant
part of patients experiencing partial response or stable disease
(Table 2) (77, 78). Figure 3 displays the Notch signaling pathway
and putative drug targets in the context of DTF.
THE JAK/STAT SIGNALING PATHWAY IN
DESMOID-TYPE FIBROMATOSIS
The JAK/STAT Signaling Pathway
The Janus-activated kinase (JAK) and signal transducer and
activator of transcription (STAT) signaling pathway regulates cell
proliferation, survival, differentiation, migration and apoptosis,
and has a role in pathogen resistance. The JAK/STAT pathway is
the main signaling mechanism for many cytokines and growth
factors. A variety of ligands e.g., interferon-α/interferon-ß (IFN),
secreted by leukocytes (IFN-α), fibroblasts (IFN-ß), and various
other cells involved in immune responses, and interleukins (IL)
together with their cognate receptors, stimulate the pathway.
Ligand binding causes receptor dimerization and subsequent
activation of the JAK tyrosine kinases associated with the
cytoplasmic domains of the receptor. JAKs in close proximity
are trans-phosphorylated and phosphorylate the receptors. The
phosphorylated receptor sites can then serve as docking sites for
cytoplasmic transcriptions factors (STATs). These STATs become
phosphorylated by JAKs, dimerize and are translocated into the
nucleus where they activate or repress the transcription of target
genes [reviewed by O’Shea et al. (110)].
The JAK/STAT Signaling Pathway in
Cancer
Dysregulation of the JAK/STAT signaling pathway has been
observed in several cancers including hematological and solid
malignancies, such as breast [reviewed by Banerjee and
Resat (111)] and prostate cancer [reviewed by Bishop et al.
(112)]. Hallmarks of JAK/STAT dysregulation are: aberrant
cytokine production, the occurrence of activating JAK mutations
or mutations in other upstream oncogenes, and activating
mutations in STAT [reviewed by O’Shea et al. (110)].
The JAK/STAT Signaling Pathway and Its
Role and Therapeutic Potential in
Desmoid-Type Fibromatosis
In both human DTF samples and murine DTF models
(Apc/Apc1638N), an increased expression of type 1 IFN response
genes (e.g.,MxA, MxB, IFITI1, and IFNAR1) have been identified
suggesting an activated JAK/STAT signaling. Genes activated
by this signaling pathway, have been shown to have an anti-
proliferative effect on DTF cells and normal fibroblasts (Table 1)
(63). Regression of DTF after treatment with IFN has been
described in several case reports (113–116). A retrospective study
by Leithner et al. examined 13 DTF patients receiving IFN-α ±
tretinoin [a natural metabolite of vitamin A (retinol)]. This study
indicated no evidence of disease in seven out of nine patients
(adjuvant group), a mean disease-free interval of 22months (±18
months), and progressive disease in two patients. Stabilization of
DTF occurred in four patients which received IFN-α ± tretinoin
(117). Despite these encouraging results, no prospective clinical
trials in DTF have been carried out yet.
THE PI3 KINASE/AKT AND mTOR
SIGNALING PATHWAYS IN DESMOID-TYPE
FIBROMATOSIS
The PI3 Kinase/AKT and mTOR Signaling
Pathways
The phosphoinositide 3 (PI3) kinase signaling pathway
plays a critical role in various cellular processes like cell
growth, survival, proliferation, metabolism and differentiation
[reviewed by Engelmann et al. (118)]. The pathway is activated
by plasma membrane proteins including receptor tyrosine
kinases, integrins, B- and T-cell receptors, cytokine receptors
and GPCRs and entails the formation of membrane-bound
phosphatidylinositol-3,3,5-triphosphate (PIP3) by the enzyme
PI3 kinase. Proteins that harbor a pleckstrin-homology
(PH) domain like AKT (protein kinase B or PKB) and
PDK1 bind to the 3-phosphoinositides on the membrane.
Subsequent phosphorylation of AKT at the Thr308 and
Ser473 residues, by PDK1 and mTORC2, respectively,
fully activates its serine/threonine kinase potential. AKT
consequently phosphorylates many downstream substrates,
thereby regulating various cellular functions [reviewed
by Hers et al. (119)]. Importantly, AKT also leads to
downstream activation of the mTOR complex 1 (mTORC1)
pathway by phosphorylation of its negative regulators
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TSC2 and PRAS40. Activation of this complex provides a
growth advantage for cells, as mTORC1 is critical for cell
maintenance by sensing nutritional and environmental cues
and responding by inhibiting autophagy and regulating
translation, thereby stimulating cell growth and proliferation
[reviewed by Hers et al. (119) and Dowling et al. (120)].
The PI3 Kinase/AKT and mTOR Signaling
Pathways in Cancer
Dysregulation of the PI3 kinase/AKT signaling pathway is
frequently encountered in cancers and facilitates tumorigenesis.
Over-activation of AKT may be caused by the presence
of gain-of-function mutations in PI3K subunits, or loss-
of- function mutations in Phosphatase and Tensin homolog
deleted from chromosome 10 (PTEN) or PTEN expression loss.
PTEN, a tumor suppressor is a lipid phosphatase, negatively
regulating AKT by dephosphorylation of PIP3. Alternatively,
overexpression or activating mutations in tyrosine kinase
receptors and their ligands, as well as the interaction of Ras with
PI3K, can excite AKT activity [reviewed by Brugge et al. (121)
and Keniry and Parsons (122)].
The PI3 Kinase/AKT and mTOR Signaling
Pathways and Their Role and Therapeutic
Potential in Desmoid-Type Fibromatosis
The relationship between DTF and the PI3 kinase/AKT and
the mTOR signaling pathways has not been extensively studied.
Immunohistochemical analysis of 29 DTF tumor samples
indicated the expression of ß-catenin and PDGFR-ß in all
samples. No expression could be detected of PDGFR-α and
phospho-Ser-473, suggesting inactive AKT signaling (123).
Meazza et al. showed that a substantial part of pediatric DTF
cases had an E17K mutation in either AKT1 (eight out of 28;
31%), however no AKT1 mutations were observed in adult
DTF cases (n = 33) (124). Interestingly, DTF patients with an
E17K AKT1 mutation had a longer recurrence free survival
rate in agreement with the mutation-induced stimulation of
downstream AKT signaling.
Recently, Rosenberg et al. reported the antitumor effect of
sorafenib, a multi-kinase inhibitor that targets multiple tyrosine
kinases (e.g., VEGFR, c-Kit, and PDGFR) expressed on patient
derived DTF cell lines (Table 1). It was found that sorafenib
decreased proliferation and invasion in a dose dependent manner
and that the Ras/MEK/ERK and the PI3 kinase/AKT/mTOR
signaling pathway were affected. Additionally, they investigated
the efficacy of everolimus, an mTOR inhibitor, as monotherapy
and in combination with sorafenib, and found no synergistic or
additive inhibitory effect on cellular proliferation (Table 1) (64).
Cates et al. compared the expression profiles of selected receptor-
and non-receptor tyrosine kinases and downstream effectors of
signaling activity in DTF (n = 27), reactive scars (n = 14) and
fibrous tissue (n= 6) (Table 1). PDGFR-β, FAK 1 and MET were
detected by IHC in almost all DTFs and scar tissues and in at
least half (PDGFR-β, FAK1) or none (MET) of the fibrous control
tissue. Of note, AKT was phosphorylated in 56% of DTF samples,
but significantly higher levels were observed in scar tissues and
only low levels were observed in a subset of fibrous tissues (125).
Inhibition of various tyrosine kinases including PDGFR
with imatinib is a promising treatment strategy for DTF.
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Imatinib is effective in other solid tumors of mesenchymal
origin like gastrointestinal stromal tumors (GISTs) and
dermatofibrosarcoma protuberans, in which it targets KIT
or PDGFR-α/PDGFR-ß [reviewed by Kosela-Paterczy and
Rutkowski (126) and Casali et al. (127)]. The efficacy of
imatinib (either alone or combined with other treatment) was
observed in several early phase clinical studies with DTF patients
(Table 2) (79–84). Chugh et al. and Penel et al. reported a 1-year
progression free survival (PFS) of 66% and 67%, respectively.
However, the results of these studies should be interpreted with
caution, since the majority of patients included in these trials
received other treatments prior to treatment with imatinib
(Table 2) Additionally, the relevant targets of imatinib in DTF
remain unclear (81, 123). Two phase II clinical trials, that
included DTF patients, studied the effect of sunitinib (Table 2).
George et al. did not detect a response to sunitinib in the single
DTF patient that was included in their study (85). In contrast,
a study by Jo et al. showed a 2-year PFS of 75% in 19 patients
with advanced DTF (86). A phase I study, investigating the
use of sorafenib in pediatric solid malignancies, of which two
patients had DTF, showed a partial response on sorafenib in
one patient (87). Recently published results from the phase 3
clinical trial (NCT02066181; sorafenib vs. placebo for advanced
and refractory DTF) showed a 2-year PFS rate of 81% (95%
confidence interval [CI] 69–96) with an objective response rate
(ORR) of 33% (95% CI, 20–48) in the sorafenib group vs. 2-year
PFS of 36% (95% CI, 22–57) and an ORR of 20% (95% CI,
8–38) in the placebo group (88). The biological mechanisms
underlying the activity of sorafenib in DTF remain unclear
because sorafenib targets multiple tyrosine kinases thereby
affecting multiple pathways.
The use of imatinib, sunitinib and sorafenib, led to study
the tyrosine kinase inhibitor (TKI) pazopanib in the setting of
DTF. Pazopanib targets the VEGFR1-3, PDGFR-α, and PDGFR-
ß, amongst others. A retrospective study by Szucs et al., described
a partial response in three out of eight patients with DTF and
stable disease in five out of eight patients with a median PFS of
13.5 months (128). Another retrospective study in adolescents
and young adults with DTF by Agresta et al. reported tumor
reduction after pazopanib use with only mild toxicities (Table 2)
(129). One clinical trial is currently ongoing to investigate TKIs
in the setting of DTF; pazopanib (NCT01876082, phase 2 study)
(Table 3) (134).
THE GROWTH FACTOR REGULATORY
SIGNALING PATHWAYS IN DESMOID-TYPE
FIBROMATOSIS
The Growth Factor Regulatory Signaling
Pathways
The superfamily of transforming growth factor-ß (TGF-
ß) regulates cell proliferation, differentiation, apoptosis and
development. Two ligand subfamilies are recognized; the TGF-
β nodal subfamily, and bone morphogenetic protein (BMP)
subfamily. Ligand binding of either TGF-β ligands or BMP
ligands facilitates the oligomerization of type I and type
II serine/threonine receptor kinases. In case of signaling,
intracellular effectors R-SMAD’s, are phosphorylated in the
cytoplasm whereupon they partner with SMAD4 and translocate
to the nucleus. In the nucleus they regulate, in conjunction
with transcription factors/corepressors or co-activators, the
transcription of TGF-ß target genes. Growth factor signaling
pathways are initiated by various growth factors (e.g., insulin-like
growth factors, platelet-derived growth factor, and hepatocyte
growth factor) and induce phosphorylation of downstream
targets via activation of their associated receptor tyrosine
kinases. The signal is transduced through various intracellular
intermediate molecules, frequently including PI3 kinase/AKT
and Ras/Raf/MAPK signaling pathways to ultimately affect gene
expression [reviewed by Massague (135)].
The Growth Factor Regulatory Signaling
Pathways and Their Role and Therapeutic
Potential in Desmoid-Type Fibromatosis
The role of TGF-ß in DTF has been established by the
expression of TGF-ß target genes (e.g. several collagen types
and metalloproteinases) and by the upregulation of TGF-β
TABLE 3 | Overview of ongoing clinical trials with targeted drugs in DTF.
Drug References NCT# Setting Current status
PI3 KINASE/AKT/mTOR SIGNALING PATHWAY
Receptor Tyrosine
Kinase inhibitor
Imatinib + vactosertib
(130) NCT03802084 Phase 1/2 clinical trial Not yet recruiting
mTOR inhibitor
Sirolimus
(131) NCT01265030 Phase 1 clinical trial
Phase 2 clinical trial (children and
young adults)
Recruiting
NOTCH SIGNALING PATHWAY
Notch inhibitor
PF-03084014
(132) NCT01981551 Phase 2 clinical trial Active, not
recruiting
(133) NCT03785964 Phase 3 clinical trial Not yet recruiting
GROWTH REGULATORY SIGNALING PATHWAY
PDGF-α/PDGF-
ß/VEGFR
Pazopanib
(134) NCT01876082 Phase 2 clinical trial Recruiting
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signaling pathway components (phospho-SMAD2 and phospho-
SMAD3, α-SMA and PAI1) in comparison to normal fascia
(66). Mignemi et al. investigated TGF-ß signaling comparing
DTF tissue with hypertrophic scars and fibrous tissue in
human samples. It was discovered that the levels of TGF-
ß receptor type 1 were similar in DTF and scar tissue, but
that this receptor could not be detected in fibrous tissue.
Phosphorylated SMAD2/3 could be detected in the majority
of DTF samples (74%) but only in a minority of scar tissues
(29%) and not at all in fibrous tissue (136). Additionally,
TGF-ß stimulates β-catenin transcriptional activity, which
indicates that this growth factor might play an important
role in the development of DTF (66). Multiple studies
reported overexpression of platelet derived growth factors and
their associated receptors (PDGFα, PDGFRα, PDGFß, and
PDGFRß) in neoplastic fibrous proliferations including DTF and
myofibromatoses (137, 138).
Various studies investigated the effect of TFG-ß and epidermal
growth factor (EGF) on DTF cell lines and stimulation
with these cytokines caused up- and down regulation of
various target genes (e.g., SMAD4), changes in β-catenin levels,
and increased production of glycosaminoglycan and collagen.
Additionally, treatment with EGF increased DTF cell motility
(Table 1) (65–68).
Cross-talk between the insulin-like growth factor (IGF)
and the estrogen receptor (ER) mediated signaling has been
demonstrated in breast-cancer cells. Activation of MAPK,
which is located downstream of IGF-1, enhances ER induced
transcription via ER phosphorylation. Therefore, it is presumed
that growth factor signaling pathways and the estrogen pathways
complement and overlap each other [reviewed byDhingra (139)].
Toremifene, a drug which also inhibits collagen synthesis and
protein kinase C, works on both the growth factor regulatory
signaling pathway and the estrogen pathway andwill be discussed
in the next section.
THE ROLE OF THE ESTROGEN DRIVEN
PATHWAY IN DESMOID-TYPE
FIBROMATOSIS
The Estrogen Driven Pathway
Estrogens affect various physiological processes that concern the
development of the reproductive system and several reproductive
functions. The role of estrogens in cancer has been described
in breast cancer and uterine tumors [reviewed by Dhingra
(139)]. Two subtypes of estrogen receptors (ER) haven been
identified; ER-α (ESR1) and ER-ß (ESR2) to which estrogens
can bind. Without the ligand, the intracellular ER is considered
to be in an inactive state, forming a complex with two heat
shock proteins (Hsp90 and Hsp56) and various other proteins.
Upon binding of the ligand estrogen, Hsp90 is detached from
the complex which leads to ER phosphorylation. Next, the ER
dimerizes and translocates to the nucleus where it can interact
with specific DNA sequences, estrogen response elements (ERE),
causing transcriptional activation [reviewed by Dhingra (139)
and Picariello et al. (140)].
The Estrogen Driven Pathway and Its Role
and Therapeutic Potential in Desmoid-Type
Fibromatosis
The role of sex hormones, particularly estrogen, in DTF
tumorigenesis is primarily based on clinical observations, and
prompted the use of anti-hormonal agents. DTF arises frequently
in females at the reproductive age (4). Moreover, tumor growth
during pregnancy, accelerated tumor growth by using oral
contraceptives and tumor regression in menopause are reported
(10, 141). Although DTF does not express ER-α, Deyrup
et al. discovered that DTF tumors express ER-ß (142). The
involvement of estrogens in DTF offers a variety of interesting
hormone related drugs which can be a potential treatment
for DTF. Tamoxifen is most extensively studied in the setting
of DTF and is often used in various dosages in combination
with other drugs, frequently NSAIDs, like sulindac [reviewed
by Bocale et al. (143)]. A meta-analysis by Bocale and Rotelli
et al. verified that tamoxifen, administered as a single agent,
gave an overall response rate (partial or complete response)
of 58% (22 out of 38 patients). In combination with NSAIDs,
this response rate decreased to 35% (143). Likewise, toremifene
has been shown to have an antitumor effect in DTF (71, 144).
Although it does not influence cell proliferation, toremifene
decreased the total amount of glycosaminoglycans (GAGs),
TGFß1, collagen and fibronectin levels and it diminished the
affinity of type I and II TGFβ1 receptors for 125I-TGF-ß1
(Table 1) (65, 70). Toremifene in retrospective clinical studies,
administered alone or in combination with other drugs like
melatonin, sulindac or IFN-α, yielded an overall complete and
partial response rate of 56%. When comparing tamoxifen and
toremifene, used as a single agent, no differences in overall
response rate were found [reviewed by Bocale et al. (143)].
Raloxifene, a drug initially developed for treating chronic
osteoporosis, was administered to 13 patients with FAP-related
DTF which were refractory to other treatments. Eight patients
displayed a complete remission and a partial response was seen
in five cases (145). Despite a clear involvement of estrogens
in DTF, response rates to anti-estrogen agents vary and the
number of prospective clinical studies is still limited. One
phase II trial combined sulindac (NSAID) with tamoxifen
in pediatric DTF patients and showed a 1-year PFS of 36%
(Table 2) (89).
FUTURE DIRECTIONS AND CONCLUSION
This review aims to provide a summary of the current knowledge
of important, cancer-related signaling pathways in the setting
of DTF. The role of Wnt/β-catenin signaling in DTF has been
firmly established in numerous studies, showing the presence
of β-catenin signaling enhancing mutations in the vast majority
of tumors. Therapeutic options targeting the Wnt/β-catenin
signaling pathway remain scarce and are not yet widely tested
in the clinical setting for DTF. Several clinical trials, targeting
other signaling pathways, like Notch andHedgehog, are currently
ongoing, but few study the contribution of these pathways to
DTF tumorigenesis.
Frontiers in Oncology | www.frontiersin.org 11 May 2019 | Volume 9 | Article 397
Timbergen et al. Signaling Pathways in Desmoid-Type Fibromatosis
A major challenge remains to study DTF in the preclinical
setting. This is partly due to the rarity of the tumor type,
but also to the limited availability of DTF cell lines and other
cell and animal models (3). Culturing a fresh DTF resection
specimen, inevitably leads to an overgrowth of WT fibroblasts
and concomitant loss of DTF tumor cells. Separating tumor cells
from their surrounding stromal cells remains challenging and
time consuming. Even if a “pure” DTF cell line is obtained, DTF
tumor cells often reach senescence after several passages. To our
knowledge, no studies investigating the effect of immortalization
protocols on primary DTF cells have been published yet.
Experimenting with primary cultures, consisting of both stromal
cells and tumor cells, is an alternative but has its drawbacks.
Additionally, representative cellular and animal models of DTF
(e.g., organoids or mice expressingmutatedCTNNB1) in relevant
tissues are difficult to generate and expensive to maintain. The
existing Apc+/Apc1638N mouse model has already been proven
as a useful model for FAP-associated DTF and is often used as
a tumor model for non-FAP related DTF (Table 1) (61, 146).
A mouse DTF model based on specific β-catenin mutations is,
to our knowledge, currently not available. A recently developed
genetically engineered Xenopus tropicalis model harboring a
mutated APC, may yield another DTF tumor model that can
be exploited as a platform to define novel therapeutic targets
and preclinical validation studies (147). Well-defined preclinical
models are as necessary as well-annotated large series of DTF
tumor samples, to better understand DTF biology and to provide
experimental support and rationale for translational research
investigating the inhibition of signaling pathways in DTF.
Additionally, signaling pathways are often seen as separate
entities, however, in reality cross-talk occurs between different
pathways. The precise interactions between different signaling-
and biochemical pathways is complex and still poorly
understood. Aberrant signaling of one pathway can often
be corrected via compensatory mechanisms in another pathway
(148). In DTF tumors and cell lines, the Wnt, Notch and
Hh signaling pathways have been shown to be involved in
cross-talk, implicating optimal therapeutic efficacy, is reached
when all interacting pathways are inhibited in a combinatorial
approach (149). Future studies should not focus on individual
signaling cascades but rather on the simultaneous inhibition of
multiple pathways.
Furthermore, clinical studies to evaluate the efficacy of
systemic and targeted treatments without any randomization
procedures remain challenging in current clinical practice as
they are often difficult to interpret. Due to the unpredictable
growth behavior of DTF with reports of spontaneous regression
without treatment and stable disease, it is difficult to distinguish
the true treatment effects from natural growth behavior.
Moreover, the design of randomized controlled trials might be
restricted by the rarity of the disease and the small number
of DTF patients with an indication for systemic treatment.
Despite these challenges, future studies should include signaling
pathways other than Wnt/β-catenin signaling to uncover
additional driver genes and pathways in DTF and to clarify the
potential working mechanisms of target drugs in the setting
of DTF.
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